Innovating to Change Lives
Our commitment to innovation, collaboration, and scientific rigor drives an ever-growing pipeline aimed at transforming patients’ quality of life. We develop life-changing medicines by combining novel target drug molecules with immuno-oncology therapies.
Our Approach
Everything we do is centered on our mission to innovate life-changing medicines for cancer patients. We are redefining cancer treatment and embracing new approaches combining targeted therapy and innate immunity to enhance a patient’s quality of life.
We leverage our deep expertise in the KRAS pathway to innovate combinatorial treatments that directly attack cancer tumors while activating the body’s systems to minimize drug resistance and rapid relapse.
By utilizing small-molecule immunotherapies, we hope to offer patients the flexibility to rapidly adapt treatments as needed.
A large part of impacting patients is being there for them. Our resilient pipeline, powered by ongoing discovery, ensures we are not relying on one or two drug candidates. Our innovative flywheel approach maximizes our potential to achieve our mission.
Kumquat Biosciences Pipeline
RAS
| KQB198 RAS pathway | Clinical Phase 1 |
| KQB365 KRAS mutant | Clinical Phase 1 |
| KQB368 KRAS mutant | IND-enabling |
| KQB548 KRAS mutant | IND-enabling |
| KQB726 KRAS pan | IND-enabling |
| KQB162 RAS pathway | IND-enabling |
Small Molecule I/O
Corporate Partnership
KQB168
Platform
Discovery Platform
| Discovery program 1 (inflammation) | Preclinical |
| Discovery program 2 (autoimmune) | Preclinical |
Preclinical
IND-enabling
Clinical Phase 1
RAS
KQB198 RAS pathway
KQB365 KRAS mutant
KQB368 KRAS mutant
KQB548 KRAS mutant
KQB726 KRAS pan
KQB162 RAS pathway
Small Molecule I/O
Corporate Partnership
KQB168
Platform
Discovery Platform
Discovery program 1 (inflammation)
Discovery program 2 (autoimmune)
Our Platform
Our proprietary platform is built on our pioneering work targeting KRAS G12C through covalent chemistry. Leveraging our deep expertise in covalent chemistry and our advanced technology for characterizing covalent inhibitors, we have transformed this approach to reach a repertoire of previously undruggable pockets in high-value targets. Our novel approach enables us to target disease proteins with ultra-high potency and selectivity, offering attractive pharmacokinetic properties, enhanced therapeutic window and durable therapeutic potential.
Foundational Science
Please see the publications below for the foundational science behind our new discoveries.
An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors – Scientific Reports
The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors – Nature
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State – AACR Journals
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions – Nature
Learn More About Our Pipeline and Programs
